ArticleFrontiers in pharmacology2022
Flos puerariae ameliorates the intestinal inflammation of
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- Article
- Xuanfei Baidu decoction alleviates intestinal inflammation and modulates microbiota distribution by suppressing IMD/NF-κB and JNK signaling pathways.Frontiers in microbiology · 2026Article
- Drosophila melanogaster models for investigating inflammatory bowel disease: Methods, pathology, mechanisms, and therapeutic approaches.Biomolecules & biomedicine · 2025Review
- Review
- The Protective Effects of Pectic Polysaccharides on Dextran Sulfate Sodium-Induced Colitis inNutrients · 2025Article
- Iturin A Potentiates Differentiation of Intestinal Epithelial Defense Cells by Modulating Keap1/Nrf2 Signaling to Mitigate Oxidative Damage Induced by Heat-Stable Enterotoxin B.Antioxidants (Basel, Switzerland) · 2025Article
- Caffeic Acid Protects Against Ulcerative Colitis via Inhibiting Mitochondrial Apoptosis and Immune Overactivation inDrug design, development and therapy · 2025Article
- Network analysis andFrontiers in pharmacology · 2025Article
- Review
- Extracts ofHylotelephiumerythrostictum (miq.) H. Ohba ameliorate intestinal injury by scavenging ROS and inhibiting multiple signaling pathways in Drosophila.BMC complementary medicine and therapies · 2024Article
- Critical Signaling Transduction Pathways and Intestinal Barrier: Implications for Pathophysiology and Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Silibinin alleviates intestinal inflammation via inhibiting JNK signaling inFrontiers in pharmacology · 2023Article
- UsingFrontiers in pharmacology · 2022Review
- Article
- Protective effect of astragalus membranaceus and its bioactive compounds against the intestinal inflammation inFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut homeostasis is important for human health, and its disruption can lead to inflammatory bowel disease (IBD). Flos Puerariae is a herb with a wide variety of pharmacological activities including antioxidant, antidiabetic, antialcoholismic and anti-inflammatory properties. However, the role of Flos Puerariae on treating IBD remains obscure. Here, we employed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.